In this webinar, learn about obesity's health burden and the evolution of drug development in obesity. The speakers will discuss about the importance of preservation of muscle mass for long term weight maintenance. They will address the different methodologies used to evaluate total energy expenditure and its components. They will also discuss about metabolic adaptation in post obese patients as well as its implication in weight regain. The featured speakers will discuss current challenges in obesity clinical trials and strategies to mitigate these challenges for future research efforts.
TORONTO, Sept. 5, 2024 /PRNewswire-PRWeb/ -- There has never been a more exciting and promising time in pharmacological research related to obesity drugs. It is now broadly accepted that obesity is not just a lack of willpower but a complex chronic disease with increased morbidity and mortality that can be managed with the right treatment.
Over the past decade or so, gut hormone-based drug development targeting obesity and type 2 diabetes indications and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) as dual or triple agonists or other complementary mode of action have increased rapidly.
Semaglutide and, most recently, tirzepatide have demonstrated that a two-digit weight loss at one year is achievable and the Phase II data with retatrutide suggest that 100 percent of patients can now achieve the 5 percent weight loss that was targeted in the past. The next stage in obesity research needs to bring affordable and accessible drugs that can lead to selective fat loss, preservation of lean body mass and long-term weight maintenance. As with many other chronic diseases, combination therapies with complementary modes of action will be required to successfully treat patients with obesity.
The objective of this webinar is to discuss the potential next steps in obesity pharmacotherapy. The expert speakers will discuss potential complementary pathogenic targets to improve the quality of the weight loss (fat loss vs lean body mass loss), minimize metabolic adaptation and facilitate long term weigh maintenance
Finally, they will focus on brain imaging and how it can help to understand eating behavior and neurocognitive measures in obesity. The webinar will conclude with the current challenges and mitigation strategies for future clinical trials in obesity.
Register for this webinar today to understand the latest advancements related to obesity pharmacotherapy.
Join Dr. Eric Ravussin, PhD, Boyd Professor, Douglas L. Gordon Chair in Diabetes and Metabolism, Pennington Biomedical Research Center-LSU System, Baton Rouge, Louisiana; Dr. Claudia Filozof, Vice President and Therapeutic Area Head in Obesity, MASH and Liver Indications, Fortrea; and Dr. Peter Alfinito, PhD, Executive Director, Operational Strategy & Planning, Fortrea, for the live webinar on Thursday, September 19, 2024, at 10am EDT (3pm BST/UK).
For more information, or to register for this event, visit New Era of Obesity Drug Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article